TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

NCT06138561 ·Status: RECRUITING

Bladder Cancer Patient-Reported Outcomes

NCT01090388 ·Status: COMPLETED

Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers

NCT03413982 ·Status: RECRUITING

Prognostic Biomarkers in Patients With Urothelial Carcinoma

NCT04872036 ·Status: COMPLETED

Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia

NCT05397262 ·Status: RECRUITING ·Phase: NA

A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

NCT06031584 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

NCT05356351 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

NCT06350734 ·Status: ACTIVE_NOT_RECRUITING

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

NCT03768570 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

NCT06178601 ·Status: RECRUITING ·Phase: PHASE2

Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer

NCT00749892 ·Status: COMPLETED ·Phase: PHASE2

Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder

NCT03529890 ·Status: UNKNOWN ·Phase: PHASE2

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer

NCT00238420 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Markers of Response to Intravesical Bladder Cancer Therapy

NCT01007058 ·Status: COMPLETED

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

NCT05137262 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Health-Related Quality of Life in Patients With Bladder Cancer

NCT00744744 ·Status: COMPLETED

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

NCT06074484 ·Status: UNKNOWN ·Phase: PHASE2

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

NCT07106762 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820 ·Status: RECRUITING ·Phase: PHASE3

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

NCT04701918 ·Status: COMPLETED ·Phase: PHASE2

Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells

NCT05108077 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Molecular Markers of Chemosensitivity for Bladder Cancer

NCT02074241 ·Status: UNKNOWN

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

NCT06488222 ·Status: RECRUITING ·Phase: PHASE2

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

NCT05979740 ·Status: UNKNOWN ·Phase: PHASE2

Quality of Life and Symptom Management in Patients With Bladder Cancer

NCT00772018 ·Status: COMPLETED